5-Hydroxyoxindole
Based on 1 Customer Validation
5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders.
For research use only. We do not sell to patients.
- Purity : 95.09%
- CAS No.: 3416-18-0
- Formula: C8H7NO2
- Molecular Weight:149.15
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
DPPH[1]
Chemical Information
-
CAS No. 3416-18-0
-
Appearance Solid
-
Molecular Weight 149.15
-
Formula C8H7NO2
-
Color Light brown to brown
-
SMILES
O=C1NC2=C(C=C(O)C=C2)C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (670.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.7047 mL | 33.5233 mL | 67.0466 mL | 167.6165 mL |
| 5 mM | 1.3409 mL | 6.7047 mL | 13.4093 mL | 33.5233 mL | |
| 10 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL | 16.7617 mL | |
| 15 mM | 0.4470 mL | 2.2349 mL | 4.4698 mL | 11.1744 mL | |
| 20 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL | 8.3808 mL | |
| 25 mM | 0.2682 mL | 1.3409 mL | 2.6819 mL | 6.7047 mL | |
| 30 mM | 0.2235 mL | 1.1174 mL | 2.2349 mL | 5.5872 mL | |
| 40 mM | 0.1676 mL | 0.8381 mL | 1.6762 mL | 4.1904 mL | |
| 50 mM | 0.1341 mL | 0.6705 mL | 1.3409 mL | 3.3523 mL | |
| 60 mM | 0.1117 mL | 0.5587 mL | 1.1174 mL | 2.7936 mL | |
| 80 mM | 0.0838 mL | 0.4190 mL | 0.8381 mL | 2.0952 mL | |
| 100 mM | 0.0670 mL | 0.3352 mL | 0.6705 mL | 1.6762 mL |